COPENHAGEN, Nov 17 (Reuters) - Novo Nordisk

has more than enough of its Wegovy weight-loss pills to support

an aggressive product launch, CEO Mike Doustdar said on Monday,

looking to avoid a repeat of the supply issues that plagued the

drug's original version.

The drugmaker expects a decision on U.S. approval before the

end of the year, with the pill format expected to appeal to

patients who prefer to avoid injections of the current Wegovy

formulation.

"We have more than enough pills this time, so we're going to

go all in and really make this happen," Doustdar said at an

event hosted by the Danish Shareholders Association.

Novo has faced slowing sales growth for the blockbuster

obesity drug that helped it to become Europe's most valuable

company. The slowdown was largely the result of supply

constraints that allowed Eli Lilly ( LLY ) and others to erode

the Danish drugmaker's first-mover advantage.

Doustdar also said that a pricing deal struck with U.S.

President Donald Trump aimed to broaden access to its

weight-loss drugs for the U.S. Medicare programme, a federal

health insurance programme for people aged 65 and older or who

have disabilities.